FILTER

FILTERED INTERVIEW RESULTS

Michael Quirmbach

CEO AND PRESIDENT, CORDENPHARMA
"Our main mission is the execution of a >€200 million investment into CapEx projects that will bring additional capacity and technologies online to support pharma and biotech customers as their drug development projects progress."

Christiana Bardon

CO-MANAGING PARTNER, MPM | BIOIMPACT CAPITAL
"We see this as an exciting time to be investing in record-high levels of innovation at very attractive valuations."

Debbie Hart

PRESIDENT AND CEO, BIONJ
"To ensure that New Jersey maintains this leadership position, BioNJ will continue to work with State government to support industry and stave off onerous proposals. "

Jay Shukla

PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS, INC.
"Our partners benefit from our market intelligence and cost-splitting, and we attain the manufacturing capability and resources. We will continue to grow our partnership model now that we are expecting to double our revenue."

Robert Poe

CEO, OLON RICERCA BIOSCIENCES
"What we are doing here is beginning the build-out of a high-potency API suite, so that we can get up to a few hundred grams made for early studies and transfer those processes to our sites in Italy for the clinical trial phase."

Manni Kantipudi & Ramesh Subramanian

CHIEF EXECUTIVE OFFICER (MK) & CHIEF COMMERCIAL OFFICER (RS), ARAGEN LIFE SCIENCES
"Overall, I believe the virtual biotech model is here to stay and companies will increasingly look at CRO/CDMO companies for assistance in taking drugs from discovery to commercialization."

Chris Garabedian

CHAIRMAN AND CEO, XONTOGENY, AND PORTFOLIO MANAGER, PERCEPTIVE XONTOGENY VENTURE (PXV) FUND
"Following a long period of significant investment in early-stage firms, our industry needs to allow existing investments across the industry to mature and show signs of success before driving new investments in preclinical-stage projects."

Tom Wilson

GLOBAL BUSINESS DEVELOPMENT LEAD, PFIZER CENTREONE
"As we get into precision medicines, therapies, parallel trials, and getting medicines to patients faster, that will require CDMOs to work together, and this is where our growth will come from."

Fabrice Panza

MANAGER GLOBAL COOL CHAIN SOLUTIONS, ETIHAD CARGO
"Etihad Cargo’s PharmaLife product has exponentially grown over the past year, and growth will trigger more physical ties between US and UAE."

James Sapirstein

CHAIRMAN, PRESIDENT, AND CEO, FIRST WAVE BIOPHARMA
“We are happy to report that we have initiated the Phase 2 SPAN adrulipase clinical and are currently screening patients for the study. We anticipate topline data by mid-2023.”

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

Latin America Petrochemicals and Chemicals 2024 - Digital Interactive

The Latin America Petrochemicals and Chemicals 2024 report, produced in alliance with APLA, explores the current state of these industries, the challenges they face, and the opportunities they offer.

PARTNER EVENTS